Insulet (PODD) revenue breakdown
By product, U.S. is the largest at 71% of fiscal 2025 revenue, growing 28% a year over 8 years.
By region, UNITED STATES is the largest at 72% of fiscal 2025 revenue; International grew fastest, 30% a year over 9 years.
Revenue by product
Fiscal years, as Insulet reports them in its 10-K filings; fiscal 2025 total $2.7B.
| Products | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| U.S. | $272M | $324M | $420M | $527M | $652M | $885M | $1.3B | $1.5B | $1.9B | 71% |
| International | $120M | $172M | $253M | $308M | $360M | $363M | $410M | $523M | $754M | 28% |
| Drug Delivery | $72M | $68M | $65M | $70M | $87M | $58M | $36M | $39M | $34M | 1% |
Revenue by region
Fiscal years, as Insulet reports them in its 10-K filings; fiscal 2025 total $2.7B.
| Regions | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| UNITED STATES | $295M | $344M | $392M | $485M | $596M | $739M | $942M | $1.3B | $1.5B | $2.0B | 72% |
| International | $72M | $120M | $172M | $253M | $308M | $360M | $363M | $410M | $523M | $754M | 28% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for PODD.
Open PODD in InvestinglyQuestions
Where does Insulet make its money?
In fiscal 2025, by product: U.S. $1.9B, International $754M, Drug Delivery $34M.
From Insulet's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.